Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay
Open Access
- 16 July 2018
- journal article
- research article
- Published by Society for Neuroscience in eneuro
- Vol. 5 (4)
Abstract
The neurodegenerative Huntington’s disease (HD) is caused by a polyglutamine (polyQ) amplification in the huntingtin protein (HTT). Currently there is no effective therapy available for HD; however, several efforts are directed to develop and optimize HTT-lowering methods to improve HD phenotypes. To validate these approaches, there is an immediate need for reliable, sensitive, and easily accessible methods to quantify HTT expression. Using the AlphaLISA platform, we developed two novel sensitive and robust assays for quantification of HTT in biological samples using commercially available antibodies. The first, a polyQ-independent assay, measures the total pool of HTT, while the second, a polyQ-dependent assay, preferentially detects the mutant form of HTT. Using purified HTT protein standards and brain homogenates from an HD mouse model, we determine a lower limit of quantification of 1 and 3 pmand optimal reproducibility with CV values lower than 7% for intra- and 20% for interassay. In addition, we used the assays to quantify HTT in neural stem cells generated from patient-derived induced pluripotent stem cellsin vitroand in human brain tissue lysates. Finally, we could detect changes in HTT levels in a mouse model where mutant HTT was conditionally deleted in neural tissue, verifying the potential to monitor the outcome of HTT-lowering strategies. This analytical platform is ideal for high-throughput screens and thus has an added value for the HD community as a tool to optimize novel therapeutic approaches aimed at modulating HTT protein levels.Keywords
Funding Information
- Vetenskapsrådet (K2013-62X-21398-04-4, K2011-61P-20945-01-3, K2014-62X-20404-08-5)
- Region Skåne ALF
- Kungliga Fysiografiska Sällskapet i Lund
- HHS | NIH | National Institute of Neurological Disorders and Stroke (R01 NS079651)
- Agence Nationale de la Recherche (ANR-11-INBS-0011, ANR-10-LABX-73)
- Institut National de la Santé et de la Recherche Médicale
- AFM-Téléthon
- Neuroscience Research Australia and the University of New South Wales
- Mental health research institute, Alfred Hospital, Victorian Forensic Institute of Medicine
- The University of Melbourne, Helen Macpherson Smith Trust, Parkinson's Victoria and Perpetual Philantropic Service
- Department of Health | National Health and Medical Research Council (1079679)
This publication has 43 references indexed in Scilit:
- Differentiation from human pluripotent stem cells of cortical neurons of the superficial layers amenable to psychiatric disease modeling and high-throughput drug screeningTranslational Psychiatry, 2013
- Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin ExpressionCell, 2012
- Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin SynthesisNeuron, 2012
- A Screen for Enhancers of Clearance Identifies Huntingtin as a Heat Shock Protein 90 (Hsp90) Client ProteinJournal of Biological Chemistry, 2012
- Huntingtin facilitates polycomb repressive complex 2Human Molecular Genetics, 2009
- Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease MiceMolecular Therapy, 2009
- Sustained effects of nonallele‐specific Huntingtin silencingAnnals of Neurology, 2009
- Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficitsProceedings of the National Academy of Sciences, 2007
- Small molecules enhance autophagy and reduce toxicity in Huntington's disease modelsNature Chemical Biology, 2007
- Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in BrainScience, 1997